The Coronavirus Brief
Sep 02, 2022
2 minutes
By Jamie Ducharme / HEALTH CORRESPONDENT
PAXLOVID, THE ANTIVIRAL DRUG touted for its ability to keep high-risk COVID-19 patients out of the hospital, works very well for seniors but provides little benefit for people younger than 65, concluded the authors of a study published in the New England Journal of Medicine in August.
For the
You’re reading a preview, subscribe to read more.
Start your free 30 days